TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31666136

Group type: EXPERIMENTAL
Intervention: Adaptive ventilation mode 2 (AVM2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adaptive mechanical ventilation according to Otis' equation (AVM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adaptive ventilation mode 2 (AVM2) in ARDS patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adaptive mechanical ventilation according to Otis' equation (AVM) in ARDS patients
Number of subjects: 20
Study: 30899953

Group type: EXPERIMENTAL
Intervention: Goal teaching method with relevant teaching materials, applying theory to practice closely, and standardizing practice.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Goal teaching method
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no teaching materials, only observation and manipulation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 27060151

Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone therapy
Number of subjects: 469
Study: 25435683

Group type: EXPERIMENTAL
Intervention: Thoracic mobilization (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thoracic manipulation (Group B)
Number of subjects: 36
Study: 23249431

Group type: EXPERIMENTAL
Intervention: Walking Program Group - supervised, progressive walking program five days per week, for up to half an hour per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal Interaction Group - one-on-one stationary interpersonal interaction time with study personnel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care Group - care as usual within their long-term care unit
Number of subjects: 0
Study: 20358414

Group type: EXPERIMENTAL
Intervention: Antivenom
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (supportive care only)
Number of subjects: 81
Study: 18671197

Group type: EXPERIMENTAL
Intervention: Topical administration of Ageratina pichinchensis extract (phytopharmaceutical formulation in lacquer solution) for 6 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group with 8% ciclopirox lacquer solution for 6 months
Number of subjects: 96
Study: 16860051

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel, 3.5 ml, vaginally, bid, for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: K-Y Jelly, 3.5 ml, vaginally, bid, for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel and K-Y Jelly
Number of subjects: 0
Study: 12842686

Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 133

Group type: COMPARATOR
Intervention: Amadeus microkeratome
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both microkeratomes
Number of subjects: 133
Study: 11001380

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 2

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 2
Study: 8853755

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg morning dosing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg evening dosing
Number of subjects: 32
Study: 1735345

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times a day for 30 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 6715083

Group type: EXPERIMENTAL
Intervention: 0.3 mg metildigoxin (Lanitop)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.4 mg beta‐acetyldigoxin (Novodigal)
Number of subjects: 24
Study: 30759183

Group type: EXPERIMENTAL
Intervention: r-aP + Td
Number of subjects: 62

Group type: COMPARATOR
Intervention: cd/Tdap
Number of subjects: 62
Study: 30581203

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: HSV‐1 infection
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: HSV‐1 seropositive participants
Number of subjects: 198
Study: 27809956

Group type: EXPERIMENTAL
Intervention: Optometrists' assessments
Number of subjects: 155

Group type: COMPARATOR
Intervention: Ophthalmologists' assessments
Number of subjects: 155

Group type: COMPARATOR
Intervention: Cost of assessment by ophthalmologists
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cost of assessment by optometrists
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Optometrists' decision-making
Number of subjects: 155
Study: 24521088

Group type: EXPERIMENTAL
Intervention: Alters related to the participant
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Alters who did not use drugs
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Alters embedded in smaller networks
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Alters with more frequent contact with the participant
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Alters' drinking history
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Alters' criminal history
Number of subjects: 270
Study: 22194637

Group type: EXPERIMENTAL
Intervention: Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 67
Study: 20657257

Group type: EXPERIMENTAL
Intervention: BBS (antibiotic-impregnated bioabsorbable bone substitute)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PMMA (antibiotic-impregnated polymethylmethacrylate cement beads)
Number of subjects: 30
Study: 17482880

Group type: EXPERIMENTAL
Intervention: Escalated-dose CFRT
Number of subjects: 843

Group type: COMPARATOR
Intervention: Standard-dose CFRT
Number of subjects: 843
Study: 14600809

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 49
Study: 12085202

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by tamoxifen
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy followed by tamoxifen
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 98
Study: 8594675

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Enzyme‐linked immunosorbent assay (ELISA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Microscopy of tissue smears
Number of subjects: 39
Study: 2765262

Group type: EXPERIMENTAL
Intervention: 3.8 fish containing meals per week for 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.5 fish containing meals per week
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2.3 fish containing meals per week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 1170

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Pentobarbital 50 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Pentobarbital 100 mg
Number of subjects: 128
Study: 31278109

Group type: EXPERIMENTAL
Intervention: Homestead Food Production (HFP) programme
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2700
Study: 29017493

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Abiraterone
Number of subjects: 200
Study: 26549586

Group type: EXPERIMENTAL
Intervention: Intravenous PEG-asparaginase (15 doses of 2500 IU/m² every 2 weeks)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Intramuscular native E coli L-asparaginase (30 doses of 25,000 IU/m² weekly)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Intravenous PEG-asparaginase
Number of subjects: 463

Group type: COMPARATOR
Intervention: Intramuscular native E coli L-asparaginase
Number of subjects: 463
Study: 23782890

Group type: EXPERIMENTAL
Intervention: Cancer registry‐contacted colorectal cancer (CRC) cases who agreed to study contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-risk relatives contacted for intervention participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer registry source
Number of subjects: 0
Study: 20733274

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.06 mg/kg/day) with Growth Hormone (GH 0.35 mg/kg/week)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Growth Hormone (GH 0.35 mg/kg/week) with Placebo (Pl)
Number of subjects: 76
Study: 19339393

Group type: EXPERIMENTAL
Intervention: Putative cancer prevention diet
Number of subjects: 896

Group type: COMPARATOR
Intervention: Diet of 5 servings of vegetables and fruit daily (Control)
Number of subjects: 896
Study: 16961610

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) added to ASA-PRP
Number of subjects: 66

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 66

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 66
Study: 12818944

Group type: COMPARATOR
Intervention: Subarachnoid isobaric lidocaine 30 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Subarachnoid hyperbaric bupivacaine 5.25 mg
Number of subjects: 59
Study: 10890135

Group type: EXPERIMENTAL
Intervention: 250 mg mefloquine administered on days 0, 1, 7, 14, 21 and 28; further 5 weekly doses of 250 mg mefloquine.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 125 mg mefloquine administered as further 5 weekly doses.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mefloquine (both dosages)
Number of subjects: 12
Study: 8851688

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg iv at 0 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Atenolol (100 mg po at -60 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Salbutamol (0.08 mg/kg po at -60 min)
Number of subjects: 6
Study: 1635441

Group type: EXPERIMENTAL
Intervention: Bronchodilator
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6369532

Group type: EXPERIMENTAL
Intervention: Cefazolin (0.5 g every 6 h for 4 days)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g every 12 h for 2 days)
Number of subjects: 569
Study: 31504495

Group type: EXPERIMENTAL
Intervention: Local coalitions promoting smoke-free policies/enforcement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 30977736

Group type: EXPERIMENTAL
Intervention: FOCUS smartphone intervention for 12 weeks
Number of subjects: 82
Study: 28545934

Group type: EXPERIMENTAL
Intervention: Weibull cure‐mixture model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Weibull model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonparametric model based on Bayesian bootstrap
Number of subjects: 0
Study: 26137975

Group type: EXPERIMENTAL
Intervention: Atacicept (150 mg subcutaneous injections once weekly for 25 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atacicept and Rituximab
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo and Rituximab
Number of subjects: 27
Study: 22796109

Group type: EXPERIMENTAL
Intervention: THC (dronabinol)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 29
Study: 20739631

Group type: EXPERIMENTAL
Intervention: CAPE-V
Number of subjects: 59

Group type: COMPARATOR
Intervention: GRBAS
Number of subjects: 59
Study: 18975334

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 5 mg orally, once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no antiresorptive treatment)
Number of subjects: 30
Study: 16871061

Group type: EXPERIMENTAL
Intervention: Oral feedback
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Videotape-assisted oral feedback
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no debriefing)
Number of subjects: 42
Study: 12661887

Group type: EXPERIMENTAL
Intervention: PeaceBuilders Intervention (PBI)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Delayed Intervention (PBD)
Number of subjects: 4000
Study: 11783101

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CDDP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 100
Study: 9365765

Group type: EXPERIMENTAL
Intervention: Fumagillin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other drug regimens (albendazole plus metronidazole, sulphadiazine plus pyrimethamine, atovaquone, doxycycline plus nifuroxazide, itraconazole, flubendazole, chloroquine, paromomycin, sparfloxacin)
Number of subjects: 60
Study: 8498397

Group type: EXPERIMENTAL
Intervention: Open-ended introduction to CAGE questions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Closed-ended introduction to CAGE questions
Number of subjects: 43
Study: 3305212

Group type: EXPERIMENTAL
Intervention: MRC UKALL VIII
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-centre therapy
Number of subjects: 0
Study: 29305129

Group type: EXPERIMENTAL
Intervention: Home-based vegetable gardening intervention delivered by cooperative extension master gardeners, including guidance to establish three seasonal vegetable gardens, with provided plants, seeds, and gardening supplies.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wait-list control arm (no intervention).
Number of subjects: 46
Study: 27613456

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 169

Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 169
Study: 25175842

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (100 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Topical ropivacaine (37.5 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 150
Study: 23050696

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (Lac) at 2 g/kg diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hydrated sodium calcium aluminosilicate (HSCAS) at 2 g/kg diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mannan oligosaccharides (MOS) at 2 g/kg diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aflatoxin (AF) at 200 ppb
Number of subjects: 5
Study: 21556992

Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LAP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Open sigmoid resection (OP)
Number of subjects: 105
Study: 18300872

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 842

Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 842

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 842
Study: 16547085

Group type: EXPERIMENTAL
Intervention: Protocol A: 2 g/kg/day of protein equivalent
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Protocol B: 1.2 g/kg/day protein equivalent
Number of subjects: 25
Study: 12535038

Group type: EXPERIMENTAL
Intervention: 15 mg.kg‐1 magnesium in 30 ml 0.9% NaCl over 20 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% NaCl alone in the same volume
Number of subjects: 40
Study: 10952794

Group type: COMPARATOR
Intervention: Subclavian catheter
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PICC line
Number of subjects: 102
Study: 9196419

Group type: EXPERIMENTAL
Intervention: Cold intermittent blood cardioplegia (CBC) with moderate hypothermic cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm continuous blood cardioplegia (WBC) with mild hypothermic cardiopulmonary bypass
Number of subjects: 20
Study: 7950448

Group type: EXPERIMENTAL
Intervention: Berodual
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atrovent
Number of subjects: 40
Study: 3552020

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HC) 400 mg daily for the first month, then 200 mg daily thereafter
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28960254

Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 0.25%
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 0.5%
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 1%
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 3%
Number of subjects: 327

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 327
Study: 29071930

Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Herbal medicine (Yupingfeng Granules)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both groups (moxibustion and control)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Moxibustion vs Herbal medicine
Number of subjects: 66
Study: 24958525

Group type: EXPERIMENTAL
Intervention: Supplementation with long-chain omega-3 polyunsaturated fatty acids (EPA and DHA) for 16 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 22813395

Group type: EXPERIMENTAL
Intervention: Suture removal instructions and equipment
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard advice and follow-up care
Number of subjects: 183
Study: 15820324

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unmedicated condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medicated condition
Number of subjects: 80
Study: 12242598

Group type: EXPERIMENTAL
Intervention: Venoruton powder 0.5 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Venoruton powder 1 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Venoruton powder 2 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Venoruton powder 4 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Venoruton powder (all doses)
Number of subjects: 16
Study: 9640122

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 40
Study: 7652030

Group type: EXPERIMENTAL
Intervention: Nicotine dose (15 micrograms/kg, approx. 1.1 mg for average subject)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2761122

Group type: EXPERIMENTAL
Intervention: NaHCO3 (E) 0.2 g.kg‐1 body wt
Number of subjects: 6

Group type: COMPARATOR
Intervention: Starch (C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NaHCO3 (E)
Number of subjects: 6
Study: 326642

Group type: EXPERIMENTAL
Intervention: Loperamide (6 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29685161

Group type: EXPERIMENTAL
Intervention: Novaloc attachment system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Locator attachment system
Number of subjects: 26
Study: 27956829

Group type: EXPERIMENTAL
Intervention: Telemonitoring with supportive phone calls during home exercise bicycle training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control phase (training without phone calls)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Telemonitoring with supportive phone calls
Number of subjects: 53
Study: 24754137

Group type: EXPERIMENTAL
Intervention: Wire fixation with ligaments repaired (Group A)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Hook-plate fixation without ligaments repaired (Group B)
Number of subjects: 127
Study: 21975451

Group type: EXPERIMENTAL
Intervention: Slow amplitude modulations (AM) at rates of 1.5, 3.5, 7.5, 15.5, and 31.5 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Four types of carrier: pure tone and 1/3‐, 2‐, and 5‐octave pink noise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Globally synchronized activity in the human auditory cortex
Number of subjects: 14
Study: 20435239

Group type: EXPERIMENTAL
Intervention: Propofol/dexmedetomidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propofol/ketamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 18307460

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study: 16120227

Group type: EXPERIMENTAL
Intervention: Stage 0 (smoking men)
Number of subjects: 22044

Group type: EXPERIMENTAL
Intervention: Stage 2 (smoking men)
Number of subjects: 22044

Group type: EXPERIMENTAL
Intervention: Stage 1 (smoking men)
Number of subjects: 22044

Group type: EXPERIMENTAL
Intervention: Stage 2 (smoking women)
Number of subjects: 22044
Study: 12153835

Group type: EXPERIMENTAL
Intervention: Outpatient commitment
Number of subjects: 184

Group type: COMPARATOR
Intervention: Released without outpatient commitment
Number of subjects: 184
Study: 10197378

Group type: EXPERIMENTAL
Intervention: albendazole plus vitamins A, C and E, selenium and zinc
Number of subjects: 0

Group type: COMPARATOR
Intervention: albendazole plus placebo
Number of subjects: 0
Study: 7790550

Group type: EXPERIMENTAL
Intervention: Injection flow: 4 ml/s (Protocol 3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection flow: 4 ml/s (60 ml) + 2 ml/s (40 ml) (Protocol 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection flow: 2 ml/s (Protocol 1)
Number of subjects: 75
Study: 2087407

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 0
Study: 387496

Group type: EXPERIMENTAL
Intervention: Choline theophyllinate 400 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31005677

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (three face-to-face consultations and two telephone consultations)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 28094472

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (control)
Number of subjects: 23
Study: 26313620

Group type: EXPERIMENTAL
Intervention: One Session Treatment (OST) with e-therapy homework maintenance program over 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline periods (no intervention)
Number of subjects: 24